Eli Lilly and Company (LLY) Gets Upgraded to a Buy by CFRA

Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to buy now. In a report released on September 26, CFRA upgraded Eli Lilly and Company (NYSE:LLY) to a Buy, setting a price target of $835.00.

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

Eli Lilly and Company (NYSE:LLY) reported a 38% growth in its revenue for fiscal Q2 2025 to $15.56 billion, driven primarily by volume growth from Zepbound and Mounjaro.

The company also increased the midpoint of its 2025 full-year revenue guidance by $1.5 billion to be in the $60 billion to $62 billion range, with reported EPS guidance raised to be in the range of $20.85 to $22.10.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.